Objective
The global Biologic drug [including Vaccines] market exceeds €500 bn with an annual growth of 8%. Biopharmaceutical companies need to be able to produce these new biologic drugs faster and cheaper to meet the needs of patients, regulators and the governments and insurance companies who are paying for these high cost therapies. Valitacell is an Irish SME which currently supplies this market and is a validated supplier to a growing number of market leaders including GE Healthcare & MedImmune.
BIOSIM will accelerate the commercialisation of our ChemStress technology platform for this industry. Scientifically
these tests measure a cell’s performance when exposed to small molecule chemicals which simulate the stresses that the cell will experience in the scaled-up manufacturing process. When applied together they can reduce the average Cell Line
Development stage of drug manufacture from 16 to 6 months and reduce the average cost from €2.3million to €1.1 million.
BIOSIM will support: the demonstration of ChemStress at 4 leading biopharmaceutical manufacturing sites resulting in the generation of a customer endorsed value proposition; productise the ChemStress platform for the Biopharmmaceutical industry; refinement, scale-up and validation of the product manufacture; priming the sales & marketing for product launch.
.
ChemStress will realise €40m of end-user product sales and support 50 jobs in the 5 years following the project. ChemStress will provide EU Biomanufacturers with the opportunity to maintain their leadership position by
implementing this disruptive innovation and realizing cost reductions. ChemStress will reduce the cost of biological drugs through lower manufacturing costs so enabling EU governments to provide these drugs to EU citizens at a lower cost.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- engineering and technology mechanical engineering manufacturing engineering
- natural sciences computer and information sciences software
- engineering and technology environmental biotechnology bioremediation bioreactors
- social sciences economics and business economics production economics productivity
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
V94 DUBLIN 2
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.